Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an extension to its active pharmaceutical ingredient (API) manufacturing plant in Singapore. This significant expansion comes with an investment of SGD 1 billion (USD 743 million) and is set to bolster Pfizer’s production capabilities with the addition of 250 new jobs. The new 429,000 sq. ft. facility will specialize in the production of APIs for antibiotics and small molecule drugs targeting cancer and pain, underscoring Pfizer’s dedication to improving patient outcomes.
Located within the Tuas Biomedical Park, Pfizer’s Singapore expansion is a strategic move that aligns with the country’s robust biomedical sciences initiative. The company first established its presence in Singapore in 2003, and the construction of the facility extension commenced in 2020. This new development is expected to not only enhance Pfizer’s manufacturing footprint but also contribute to Singapore’s reputation as a biomedical hub.
The expansion is designed to be environmentally sustainable, achieving a Green Mark gold certification, which is the Singapore accreditation for environmental sustainability. This is in line with Pfizer’s goal to achieve net-zero emissions by 2040. The new facility will also be equipped with advanced manufacturing technologies to ensure the highest standards of quality and efficiency.
Pfizer’s API plant expansion comes on the heels of other major pharmaceutical companies, such as AstraZeneca, AbbVie, Novartis, GSK, and Merck, Sharp & Dohme, which have also announced new or expanded facilities in Singapore in recent years. This trend highlights the attractiveness of Singapore’s pro-business environment, skilled workforce, and strong infrastructure for biopharmaceutical manufacturing.
The new facility is expected to commence commercial manufacturing operations, further strengthening Pfizer’s global supply network and its ability to deliver life-changing medicines to patients worldwide. This expansion also signals Pfizer’s confidence in the Singaporean market and its potential for future growth in the Asia-Pacific region.- Flcube.com
